ABC transporter 3.5–3.5.4, 4.4.5
acetylators, fast vs. slow 4.4.7
N-acetyl-p-benzoquinone imine (NAPQI) 4.4.4
acetylsalicylic acid 1.1.3, 1.3.8, 9.5, 9.5.1
discovery 1.3.8
N-acetyltransferase 2 4.4.6–4.4.7
ACPD 15.1.1
action potential 6.2.4, 6.3.3–6.3.4
acyclovir 11.10.6
adenylate kinase 10.5.2
adrenal gland 12.4.3
adrenergic 5.7.3
adrenergic receptor 6.14–6.14.1
adrenergic receptors 1.1.3, 2.1.3, 3.4.4
adrenocorticotropic hormone 7.2
AG 957 12.2.2
agonist 2.1.2
aldehyde dehydrogenase 8.7.1
alendronate 7.5.4
alkaloid 1.3.4
alkylating anticancer drugs 12.6.16–12.6.19
allergies 1.2.3
allosteric 2.1.2
α-motoneuron 6.1.5
amantadine 11.10.2
amikacin 13.2.3
amino acid conjugation 4.4.9
p-aminohippurate 3.7.11
amoxicillin 3.6.8
amphetamine 6.14.3
analgesic 3.4.6
angina pectoris 8.7
antagonist 2.1.2
antidepressant 1.1.2
antimetabolites 1.3.3
antimicrobial resistance 11.2.4–11.3.1
antisense oligonucleotide 13.3.1–13.3.2
antisense oligonucleotides 1.2.2
antitarget 15.1
aorta 3.7.2
l-AP4 15.1.1
aptamer 13.3.7
aripiprazole 2.4.4
l-aromatic amino acid transporter 10.2.2
\textscl-aromatic amino acid transporter 3.5.5
aromatic hydrocarbons, carcinogenesis by 4.4.2–4.4.3
arsphenamine 1.3.1
artemisinin 11.9
arteriole 3.3.1
arylamines
metabolic activation as carcinogens 4.4.8
ataluren 13.3.4
atenolol 6.14.1
atherosclerosis 9.5.1, 10.6–10.6.2
autonomic nervous system 6.13–6.13.2
aztreonam 11.4.10
baclofen 6.10.9
batrachotoxin 6.5.4
Bay 57-1293 11.10.5
BCRP (breast cancer resistance protein) 3.5.4
benign tumor 12.1.1
benserazide 14.3.1
benzopyrene 4.4.2
benzoylecgonine 4.1.3
benztropine 6.15.2
β-lactamase 11.4.11
biliary 4.1.5
bis-chloroethyl-nitrosurea 12.6.16, 14.4.2
blood brain barrier 3.3.3, 3.5.3
blood clots
urokinase therapy 1.1.2
blood coagulation 10.6.7–10.6.8
Blue mite©2.7
bone matrix 7.5.1
bortezomib 12.6.14
bromadiolone 10.6.8
bromocriptine 6.12.2
5-bromouracil-deoxyriboside 12.6.4
busulfan 12.6.16
caffeine 6.16.1
calcium channel 6.7–6.7.4, 6.9.1
calicheamicin γ 14.5.2
calmodulin 2.6
canfosfamide 4.4.5
capsid 11.10
carbamoylcholine 6.15.1
carbenicillin 14.2.1
carbidopa 14.3.1
carcinoma 12.5
cardiac arrhythmias 2.1.4
carindacillin 14.2.1
caspofungin 11.8.2
catecholamine 5.7.3
Cay 10471 9.6
cefotaxime 11.4.10
ceftobiprole 11.4.10
ceftriaxone 15.2.3
channel block 6.5.3
chloramphenicol 11.5.1, 13.2.4
chloroquine 11.9.1
cidofovir 11.10.5
cinacalcet 7.5.4
ciprofloxacin 11.6
cisplatin 12.6.16
clavulanic acid 11.4.11
clomiphene 7.4.9
clonidine 6.14.1
clopidogrel 5.1.1
clozapine 6.12.2
colchicine 3.5.4
complement system 14.4.5
cooperativity 2.5.1
corticotropin releasing hormone 7.2
cp-113,818 10.6.5
CP96345 5.4.1
creatinine clearance 3.7.10
cyclizine 1.2.3
cyclodextrins 14.4.3
cyclooxygenase 4.5.1, 9.3–9.5.2
cyclophosphamide 12.6.16
d-cycloserine 11.4.5
cys-loop receptor family 6.10.8
cystic fibrosis 13.3.5
cytochrome P450 3.3.3, 4.2–4.2.5, 8.7.2
cytosine arabinoside 12.6.7
daptomycin 11.7.2
daunorubicin 12.6.19
desipramine 6.14.3
desmopressin 7.2.3
dexamethasone 7.4.5
dextran 1.2.2
diabetes mellitus 10.5
diaphorase 4.5.6
diazoxide 6.6.3
diclofenac 9.4.1
didanosine 11.10.5
diethylamine 6.5.2
diethylstilbestrol 7.4.9
differentiation 12.5.1
diffusion potential 6.2.1
digitoxin 6.8.5
digoxin 6.8.5
dihydropyridine receptor 6.7.1
diisopropylfluorophosphate 6.15.4
dimethylphenylpiperazinium 6.15.1
divicine 4.5.2
dopamine
l-DOPA as prodrug of 3.5.5
receptors, aripiprazole binding to 2.4.4
drug absorption 3.2
drug application
routes of 3.2.1
drug conjugation
overview 4.4
drug development
and approval 1.3.11
drug discovery
indroductory examples 1.3–1.3.10
drug distribution 3.2
drug elimination 3.2
drug targets
drugs
and poisons, relationship according to Paracelsus 1.1.1
principles of action see pharmacodynamics
drugs development
and approval 1.3.11
EC502.7
Edman degradation 6.10.5
edrophonium 6.15.5
Ehrlich, Paul 1.3.1
eicosanoids 9.1
elacridar 3.5.3
enalaprilate 1.2.6
endocrine 7.2
endothelium 3.3.2, 8.2–8.2.2, 10.6.2
enfuvirtide 11.10.4
enteric coating 14.4.1
ephedrine 3.4.4
epinephrine 2.3.4
epithelium 3.4.5
eplerenone 7.4.7
equilibrium potential 6.2.2
erythromycin 4.2.3, 11.3, 15.2.5
ethinylestradiol 7.4.9
ethosuximide 6.7.3
etoposide 12.6.12
excitation-conduction system 6.1.5, 6.3.5
excitation-contraction coupling 6.7.1
excitatory postsynaptic potential 6.9.2
exemestane 12.4.2
exocrine 7.2
exp7711 14.2.2
ezetimibe 10.6.5
false transmitter 6.14.2
famotidine 1.2.4
finasteride 7.4.9
Fleming, Alexander 1.3.9
flucytosine 11.8.2
fludrocortisone 7.4.7
fluorescence resonance energy transfer 5.2.1
5-fluorouracil 12.6.1
fluoxetine 6.14.3
flutamide 7.4.9
follicle-stimulating hormone 7.4.9
foscarnet 11.10.5
fosfomycin 11.4.4
fusidic acid 11.6
gemtuzumab ozogamicin 14.5.2
genetic knockout 15.1
glia cells 3.3.2
gludopa 14.3.2
glutamine conjugation 4.4.9
glutathione-S-transferase 4.4.3
glutathione-S-transferase
activation of canfosfamide 4.4.5
Goldman equation 6.2.4
GPCR kinase 5.7.1
G protein cycle 5.1.3
Gram-positive 11.2.1
growth hormone 7.2.2
GSK1016790A 6.7.5
guanethidine 6.14.1
6-guanidinonaltrindole 5.6.3
guanylhistamine 1.2.4
GW274150 8.8
H-89 5.7.3
Hata, Sahachiro 1.3.1
hemagglutinin 11.10.1
hepatic 3.6.8
heroin 3.4.5
hexamethonium 6.15.2
histamine receptors 1.2.3–1.2.4
antagonists, development 1.2.4
HMG-CoA reductase 10.6.6
Hoffmann, Felix 1.3.8
HU-308 9.7.4
humanized antibody 14.5.1–14.5.2
hydralazine 4.4.7
6-hydroxy-l-DOPA 6.12.2
hydroxyethyl-starch 1.2.2
5-hydroxytryptamine see serotonin
hyperpolarization 5.3.1, 6.3.4
hypertensive crisis 1.2.7, 8.4.2
hypothalamus 7.2
131I− 7.3.5
ibuprofen 3.6.8
idoxuridine 12.6.4
imatinib 3.5.4, 12.5.5, 15.3.7
imipenem 11.4.9
imipramine 6.14.3
indomethacin 9.4.1
inferior vena cava 3.7.2
inhibitory postsynaptic potential 6.9.2
inositoltriphosphate 5.3.2, 8.4.2
insulin 14.6
interstitial space 3.6.6
intravascular 1.1.2
inulin 3.7.9
inverse agonist 2.4.4
ion channel 6.2.3
ionophore 11.7.1
ipratropium 1.3.4
ipratropium bromide 6.15.2
iptakalim 6.6.3
isoflurane 6.10.9
isoniazid 11.4.2
isosorbide dinitrate 8.7
isouramil 4.5.2
ivermectin 6.10.10
labetalol 2.1.3
lead compound 15.1
lead compounds 1.3
leak channels 6.2.4
letrozole 12.4.2
leukocytes 3.2.2
leuprolide acetate 14.7
lidocaine 6.5.2
ligand see also receptor
ligand-gated ion channel 6.9.3
lipopeptide 11.7.2–11.7.4, 11.8.2
lipopolysaccharide 11.4.1, 11.7.3–11.7.4
lithium 1.1.2
lomitapide 10.6.5
low density lipoprotein 10.6.2–10.6.3
luteinizing hormone 7.4.9
malaria 2.1.4
malathion 6.15.5
malignancy 12.1.1
malignant lymphoma 10.3.10
MDMA (ecstasy) 6.14.3
MDR-1 3.5.1
mechlorethamine 12.6.16
medronate 7.5.4
melarsene oxide 11.9.3
melphalan 12.6.16
membrane potential 3.7.11
meperidine 6.14.7
metamphetamine 3.4.4
metastases 12.1.1
methadone 6.16.2
methicillin 11.4.9
methimazole 7.3.6
α-methyldopa 6.14.1
N-methyl-4-phenyl-tetrahydro-pyridine 6.14.7
methyltestosterone 7.4.9
metronidazole 11.9
mevastatin 10.6.6
mexiletine 6.5.4
mibefradil 6.7.3
miltefosine 11.9
mineralocorticoids 7.4.6–7.4.7
minoxidil sulfate 6.6.3
molsidomine 8.7.3
monoamine oxidase 6.14.4–6.14.7
monoamine transmitter 5.7.3
glucuronic acid conjugation 4.4.1
motor endplate 6.10.8
moxalactam 11.4.10
muscarine 6.15.1
muscarinic acetylcholine receptor 6.13.2
muscimol 6.10.9
myasthenia gravis 6.15.5
mycobacteria 11.2.1
myocardial infarction 1.1.2
urokinase therapy 1.1.2
naloxone 6.16.2
NAPQI 4.4.4
Nernst equation 6.2.2
neuron 6.1.3
neurons 1.2.2
neurotransmitter 1.2.1, 5.4.1, 6.9.1
neurotransmitter receptors 2.1.2
nevirapine 11.10.5
nicotine 6.15.1
nicotinic acetylcholine receptor 2.8, 6.10.1–6.10.7, 6.13.2
nifedipine 6.7.3
nitazoxanide 11.9
nitric oxide synthase 8.3–8.3.1
l-N-nitroarginine methyl ester 8.8
nitroglycerin 8.7
norepinephrine 2.3.4
norgestrel 7.4.9
NTBC 10.2.1
nuclear hormone receptor 4.3, 7.1
nystatin 14.4.6
ochratoxin A 10.2.3
olanzapine 3.6.8
oncoprotein 12.5
Org 29535 6.10.10
organic anion transporter 3.5
orthosteric 2.1.2
oseltamivir 11.10.3
22-oxacalcitriol 7.5.4
oxytocin 7.2.3
pancreatic islets 6.6.2
pancuronium 6.15.2
Paracelsus’ maxim 1.1.1
parasympathetic nervous system 2.8, 6.13.1
parathyroid hormone 7.5.2
Parkinson’s disease 3.5.5
Parkinson’s disease 6.12.2
paromomycin 13.2.2
partial agonist 2.4.4
patch clamp technique 6.4.2
pemetrexed 12.6.6
penicillin
antibacterial spectrum 1.3.10
penicillin G 11.4.9
penicillin g 1.1.3
Penicillium notatum 1.3.9
pentylenetetrazol 6.10.9
peptidoglycan 11.4.1, 11.4.3–11.4.7
P-glycoprotein 3.5.1
phagocytosis 8.6
pharmacodynamics 2.1
pharmacophore 15.3.9
phase I metabolism 4.1.7
phase II metabolism 4.1.7
phase III metabolism 4.1.5
phenobarbital 4.1.4, 4.3, 6.10.8
phenol 6.5.2
phenotypic screening 1.3
phospholipase C 2.5.4, 2.6, 5.3.2
photoaffinity labeling 6.10.3–6.10.5
physiology 1.1
physostigmine 6.15.5
pilocarpine 6.15.1
piroxicam 9.4.2
planar lipid bilayer 6.4.1
polyene antibiotics 11.8.1
polymyxin B 11.7.3
polyprotein 1.3.5
potency 2.7
prednisolone 7.4.5
primaquine 4.5.5
probenecid 3.7.11
procainamide 4.4.7
propranolol 3.6.4
prostaglandins 1.3.8
protein phosphorylation 2.6
ptc124 13.3.4
pulmonary 3.2.1
puromycin 11.5.2
pyrimethamine 11.2.3
ramatroban 9.6
reactive oxygen species 4.5.4, 9.3.4, 10.6.2, 11.9.1
receptor 2.1.1
concept, invention of 2.1.1
orthosteric vs. allosteric ligand binding 2.1.2
receptor desensitization 6.10.6
receptor occupancy 2.2.1
receptor tyrosine kinase 7.1
receptors
effects of drugs on 2.1.2
Red forte™ 2.7
remikiren 1.2.6
renal 3.7.8
reserpine 6.14.3
resorption ester 3.4.5
resting potential 6.1.2
retigabine 6.6.3
retinoic acid 12.5.3
retinoid X receptor 7.1, 7.3.1
rheumatism 8.8
rhodopsin 5.4
ribostamycin 13.2.1
rimantadine 11.10.2
RITA 12.2.2
rivastigmine 6.15.5
RNA interference 13.3.6
rofecoxib 9.4
RU 24858 7.4.5
ryanodine receptor 6.7.1
salbutamol 5.1.1
salicylic acid 1.3.8
salvage pathway 10.3.2, 10.3.3, 10.3.6, 12.6.1, 12.6.8
saralasin 1.2.7
sarcoma 12.3.1
SC560 9.4
Scatchard plot 2.2.3
second messenger 2.6
selective toxicity 11.1
septicemia 8.6
serotonin 2.4.4
sildenafil 8.8.1
sitosterol 10.6.5
sleeping sickness 11.9.3
sodium channels 2.1.4
sodium nitroprusside 8.7
sodium-potassium ATPase 6.8–6.8.5
soluble guanylate cyclase 8.4
spatial summation 6.9.2
spironolactone 7.4.7
spleen 2.3.4
stanozolol 7.4.9
Staphylococcus aureus 1.3.9
Stone, Edmund 1.3.7
streptomycetes 11.2.1
streptozotocin 12.6.16
stroke 1.1.2
urokinase therapy 1.1.2
strychnine 6.10.10
substance P 5.4.1
succinylcholine 6.15.1
succinylsulfathiazole 14.2.4
sulfamidochrysoidine 1.3.3
sulfanilamide 1.3.3
sulfathiazole 14.2.4
sulfonamides 1.3.3, 11.2.3, 14.2.4
sulindac 4.5.1
sympathetic nervous system 2.8, 6.13.1
synapse 6.1.3
afferent vs. efferent 6.1.3
tamoxifen 12.4.1
target validation 15.1
taxol 12.2.2
tecadenoson 6.16.1
temporal summation 6.9.2
tenofovir disoproxil 11.10.5
terbinafine 11.8.2
terfenadine 4.2.2
tetanus toxin 6.10.8
tetracyclins 11.3
Δ9-tetrahydrocannabinol 9.7.4
tetrodotoxin 6.5.4
theophylline 6.16.1
therapeutic range 3.8.1
thioredoxin 4.5.1
thyroid-stimulating hormone 7.2, 7.2.2, 7.3.5
thyrotropin-releasing hormone 7.2.2
tiagabine 6.10.9
ticarcillin 11.4.9
ticlopidine 6.16.1
tight junction 3.3.3
tight junctions 3.3.2
tissue plasminogen activator 10.6.7
tobramycin 13.2.1
tolazoline 2.3.3
tolbutamide 6.6.3
topotecan 12.6.12
transient receptor potential channel 6.7.5
tranylcypromine 6.14.6
trastuzumab 14.5
Treponema pallidum 1.3.1
trimethaphan 6.15.2
trimethoprim 11.2.3
trimetrexate 12.6.6
trypanosomes 11.9.3
d-tubocurarine 6.15.2
tyramine 6.14.3
valinomycin 11.7.1
vancomycin 11.4.12
vascular 1.2.5
vasodilation 8.2.1
vasopressin 7.2.3
venule 3.3.1
verapamil 6.7.3
vinblastine 12.6.15
warfarin 10.6.8
zosuquidar 3.5.3